Claims

1. A compound of formula (I):



wherein:

R^1 represents substituted or unsubstituted heterocyclyl;

Y represents $-(CR_{na}R_{nb})_n-$;

R_{na} and R_{nb} are each independently hydrogen or C_{1-6}alkyl;

n is an integer from 1 to 5;

R^2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;

R^3 and R^4 each independently represent hydrogen or C_{1-6}alkyl;

and salts and solvates thereof;

with the proviso that the following compounds are excluded;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[2-(2-oxoimidazolidin-1-yl)ethyl]urea;

tert-butyl 4-({[({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)carbonyl]amino}methyl)piperidine-1-carboxylate;

N-{[1-(cyclopropylcarbonyl)piperidin-4-yl]methyl}-N'-{[(2S)-4-(3,4--dichlorobenzyl)morpholin-2-yl]methyl}urea, and;

N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-{[1-(methylsulfonyl)piperidin-4-yl]methyl}urea.

2. A compound of formula (I) according to claim 1 wherein R^1 is unsubstituted or substituted piperidinyl.

3. A compound of formula (I) according to claim 1 or claim 2 wherein R^1 is selected from 1-(methylaminocarbonyl)piperidin-4-yl, 1-(diethylaminocarbonyl)piperidin-4-yl, 1-(methoxycarbonyl)piperidin-4-yl, 1-(cyclopropylaminocarbonyl)piperidin-4-yl, 1-(ethylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylaminocarbonyl)piperidin-4-yl, 1-(ethoxycarbonyl)piperidin-4-yl, 1-(tert-butoxycarbonyl)piperidin-4-yl and 1-(aminocarbonyl)piperidin-4-yl.

4. A compound of formula (I) according to any one of the preceding claims wherein R_{na} and R_{nb} are both hydrogen.

5. A compound of formula (I) according to any one of the preceding claims wherein n is 1.

6. A compound of formula (I) according to any one of the preceding claims wherein R^3 and R^4 are both hydrogen.

7. A compound of formula (I) according to any one of the preceding claims wherein R^2 is unsubstituted or substituted phenyl.

8. A compound of formula (I) according to any one of the preceding claims wherein R^2 is phenyl substituted with chloro.

9. A compound of formula (I) according to any one of the preceding claims wherein R^2 is 3,4-dichlorophenyl.

10. A compound of formula (I) according to claim 1 selected from the Examples.

11. A compound of formula (I) according to claim 10 selected from Examples 1, 2, 3, 6, 4, 5, 7, and 8.

12. A compound of formula (I) according to claim 10 selected from Examples 1, 2, and 3.

13. A process for the preparation of a compound of formula (I) as defined in claim 1 which process comprises the reaction of a compound of formula (II) with a compound of formula (III);



(II)



(III)

wherein;

R^1, Y, R^3, R^4, and R^2 are as hereinbefore defined for formula (I) in claim 1 and U is a urea-forming group;
and thereafter, if required, carrying out one or more of the following optional steps:

(i) converting a compound of formula (I) to a further compound of formula (I);
(ii) removing any necessary protecting group;
(iii) preparing a salt or solvate of the compound so formed.

14. A compound of formula (III)



(III)

wherein U is a urea-forming group and R^2 and R^4 are as defined for formula (I) in claim 1.

15. A compound of formula (IVBR)



(IVBR)

wherein A is a protected amino group and R^2 is as defined for formula (I) in claim 1.

16. A compound of formula (IVBE)



(IVBE)

wherein A is a protected amino group and R^2 is as defined for formula (I) in claim 1.

17. A compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.

18. A compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. asthma or rhinitis.

19. Use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.

20. A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition e.g. asthma or rhinitis, which method comprises administering an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.

21. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.